Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine

Pediatric Infectious Disease Journal

Volumn 27, Issue 10, 2008, Pages 874-880

  Ciarlet, Max ^a   Sani Grosso, Ramei ^a   Yuan, Guojun ^a   Liu, Guanghan F ^a   Heaton, Penny M ^a   Gottesdiener, Keith M ^a   Arredondo, José L ^b   Schödel, Florian ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Instituto Nacional de Rehabilitatión   (Mexico)

Author keywords

Concomitant use; Oral poliovirus vaccine; Pentavalent rotavirus vaccine; Rotavirus; Rotavirus gastroenteritis

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; NEUTRALIZING ANTIBODY; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; ORAL POLIOMYELITIS VACCINE; VIRUS ANTIBODY;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; COLIC; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEMOGRAPHY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEVER; HISPANIC; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; INFLUENZA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE CONGESTION; OPEN STUDY; PAIN; PHARYNGITIS; POLIOMYELITIS VIRUS 1; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; ROTAVIRUS; SEROTYPE; SIDE EFFECT; STATISTICAL ANALYSIS; VIRAL GASTROENTERITIS; VOMITING; BLOOD; GENETIC REASSORTMENT; IMMUNOLOGY; INTUSSUSCEPTION; ORAL DRUG ADMINISTRATION; POLIOMYELITIS VIRUS; SERODIAGNOSIS; VIRUS INFECTION;

ADMINISTRATION, ORAL; ANTIBODIES, VIRAL; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INTUSSUSCEPTION; MALE; NEUTRALIZATION TESTS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; REASSORTANT VIRUSES; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES;

EID: 54049108199     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181782780     Document Type: Article

References (15)

1. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine in preventing rotavirus gastroenteritis and reducing associated healthcare resource utilization. N Engl J Med. 2006;354:23-33.
2. Rodriguez ZM, Goveia MG, Stek JE, et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatr Infect Dis J. 2007;26:221-227.
3. Giammanco G, De Grandi V, Lupo L, et al. Interference of oral poliovirus vaccine on RIT 4237 oral rotavirus vaccine. Eur J Epidemiol. 1988;4:121-123.
4. Hanlon P, Hanlon L, Marsh V, et al. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet. 1987;1:1342-1345.
5. Migasena S, Simasathien S, Samakoses R, et al. Simultaneous administration of oral rhesus-human reassortant tetravalent (RRV-TV) rotavi- rus vaccine and oral poliovirus vaccine (OPV) in Thai infants. Vaccine. 1995;13:168-174.
6. Rennels MB, Ward RL, Mack ME, Zito ET. Concurrent oral poliovirus and rhesus-human reassortant rotavirus vaccination: effects on immune responses to both vaccines and on efficacy of rotavirus vaccines. J Infect Dis. 1996;173:306-313.
7. Vodopija I, Baklaic Z, Vlatkovic R, Bogaerts H, Delem A, Andre FE. Combined vaccination with live oral polio vaccine and the bovine rotavirus RIT 4237 strain. Vaccine. 1986;4:233-236.
8. Sutter RW, Olen MK, Cochi SL. Poliovirus vaccine-live. In: Plotkin SA, Orenstein WA, eds. Vaccines. 4th ed. Philadelphia, PA: Elsevier Inc.; 2003:651-705.
9. Ward RL, Knowlton DR, Zito ET, Davidson BL, Rappaport R, Mack ME. Serologic correlates of immunity in a tetravalent reassortant rota- virus vaccine trial: US Rotavirus Vaccine Efficacy Group. J Infect Dis. 1997;176:570-577.
10. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213-226.
11. Velazquez FR, Matson DO, Guerrero ML, et al. Serum antibody as a marker of protection against natural rotavirus infection and disease. J Infect Dis. 2000;182:1602-1609.
12. Block SL, Vesikari T, Goveia MG, et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics. 2007;119:11-18.
13. Vesikari T, Clark HF, Offit PA, et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rota- virus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine. 2006;24:4821-4829.
14. Vesikari T, Itzler R, Matson DO, et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). Int J Infect Dis. 2007; 11(suppl 2):S29-S23.
15. Haber P, Baggs J, Patel M, et al. Update of RotaTeq vaccine reports to VAERS, 3/1/06-9/25/07. Presented at: The Advisory Committee on Immunization Practices, Atlanta, GA; October 25,2007. Available at: http:// www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-oct07/31RV.pdf. Accessed November 19, 2007.